Cortactin expression assessment improves patient selection for a watchful waiting strategy in pT1cN0-staged oral squamous cell carcinomas with a tumor infiltration depth below 4 mm

Koos Boeve; Mirjam F Mastik; Lorian Slagter-Menkema; Boukje A C van Dijk; Jan L N Roodenburg; Bernard F A M van der Laan; Max J H Witjes; Bert van der Vegt; Ed Schuuring

doi:10.1002/hed.26746

Cortactin expression assessment improves patient selection for a watchful waiting strategy in pT1cN0-staged oral squamous cell carcinomas with a tumor infiltration depth below 4 mm

Koos Boeve, Mirjam F Mastik, Lorian Slagter-Menkema, Boukje A C van Dijk, Jan L N Roodenburg, Bernard F A M van der Laan, Max J H Witjes, Bert van der Vegt, Ed Schuuring^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)

94 Downloads (Pure)

Abstract

Background In this feasibility study we aimed to evaluate the value of previously reported molecular tumor biomarkers associated with lymph node metastasis in oral squamous cell carcinoma (OSCC) to optimize neck strategy selection criteria.

Methods The association between expression of cortactin, cyclin D1, FADD, RAB25, and S100A9 and sentinel lymph node status was evaluated in a series of 87 (cT1-2N0) patients with OSCC treated with primary resection and SLNB procedure.

Results Tumor infiltration depth and tumor pattern of invasion were independent prognostic markers for SLN status, while none of the tumor makers showed a better prognostic value to replace SLNB as neck staging technique in the total cohort. However, in the subgroup of patients with pT1N0 OSCC, cortactin expression (OR 16.0, 95%CI 2.0-127.9) was associated with SLN classification.

Conclusions Expression of cortactin is a promising immunohistochemical tumor marker to identify patients at low risk that may not benefit from SLNB or END.

Original language	English
Pages (from-to)	2688-2697
Number of pages	10
Journal	Head and Neck: Journal of the Sciences and Specialties of the Head and Neck
Volume	43
Issue number	9
Early online date	19-May-2021
DOIs	https://doi.org/10.1002/hed.26746
Publication status	Published - Sept-2021

Keywords

lymph node classification
molecular marker
oral cancer
oral squamous cell carcinoma
sentinel lymph node biopsy
SENTINEL NODE BIOPSY
LYMPHATIC DRAINAGE PATTERNS
ELECTIVE NECK DISSECTION
11Q13 AMPLIFICATION
FADD EXPRESSION
CYCLIN D1
CANCER
OVEREXPRESSION
METASTASIS
PREDICTOR

Access to Document

10.1002/hed.26746Licence: CC BY-NC

Cortactin expression assessment improves patient selection for a watchful waiting strategy in pT1cN0‐staged oral squamous cell carcinomas with a tumor infiltration depth below 4 mmFinal publisher's version, 1.25 MBLicence: CC BY-NC

Handle.net

Persistent link

Cite this

Boeve, K., Mastik, M. F., Slagter-Menkema, L., van Dijk, B. A. C., Roodenburg, J. L. N., van der Laan, B. F. A. M., Witjes, M. J. H., van der Vegt, B., & Schuuring, E. (2021). Cortactin expression assessment improves patient selection for a watchful waiting strategy in pT1cN0-staged oral squamous cell carcinomas with a tumor infiltration depth below 4 mm. Head and Neck: Journal of the Sciences and Specialties of the Head and Neck, 43(9), 2688-2697. https://doi.org/10.1002/hed.26746

@article{38e4eef3c603464697314d79966a4058,

title = "Cortactin expression assessment improves patient selection for a watchful waiting strategy in pT1cN0-staged oral squamous cell carcinomas with a tumor infiltration depth below 4 mm",

abstract = "Background In this feasibility study we aimed to evaluate the value of previously reported molecular tumor biomarkers associated with lymph node metastasis in oral squamous cell carcinoma (OSCC) to optimize neck strategy selection criteria.Methods The association between expression of cortactin, cyclin D1, FADD, RAB25, and S100A9 and sentinel lymph node status was evaluated in a series of 87 (cT1-2N0) patients with OSCC treated with primary resection and SLNB procedure.Results Tumor infiltration depth and tumor pattern of invasion were independent prognostic markers for SLN status, while none of the tumor makers showed a better prognostic value to replace SLNB as neck staging technique in the total cohort. However, in the subgroup of patients with pT1N0 OSCC, cortactin expression (OR 16.0, 95%CI 2.0-127.9) was associated with SLN classification.Conclusions Expression of cortactin is a promising immunohistochemical tumor marker to identify patients at low risk that may not benefit from SLNB or END.",

keywords = "lymph node classification, molecular marker, oral cancer, oral squamous cell carcinoma, sentinel lymph node biopsy, SENTINEL NODE BIOPSY, LYMPHATIC DRAINAGE PATTERNS, ELECTIVE NECK DISSECTION, 11Q13 AMPLIFICATION, FADD EXPRESSION, CYCLIN D1, CANCER, OVEREXPRESSION, METASTASIS, PREDICTOR",

author = "Koos Boeve and Mastik, {Mirjam F} and Lorian Slagter-Menkema and {van Dijk}, {Boukje A C} and Roodenburg, {Jan L N} and {van der Laan}, {Bernard F A M} and Witjes, {Max J H} and {van der Vegt}, Bert and Ed Schuuring",

note = "{\textcopyright} 2021 The Authors. Head & Neck published by Wiley Periodicals LLC.",

year = "2021",

month = sep,

doi = "10.1002/hed.26746",

language = "English",

volume = "43",

pages = "2688--2697",

journal = "Head and Neck: Journal of the Sciences and Specialties of the Head and Neck",

issn = "1043-3074",

publisher = "Wiley",

number = "9",

}

Boeve, K, Mastik, MF, Slagter-Menkema, L, van Dijk, BAC , Roodenburg, JLN, van der Laan, BFAM, Witjes, MJH , van der Vegt, B & Schuuring, E 2021, 'Cortactin expression assessment improves patient selection for a watchful waiting strategy in pT1cN0-staged oral squamous cell carcinomas with a tumor infiltration depth below 4 mm', Head and Neck: Journal of the Sciences and Specialties of the Head and Neck, vol. 43, no. 9, pp. 2688-2697. https://doi.org/10.1002/hed.26746

Cortactin expression assessment improves patient selection for a watchful waiting strategy in pT1cN0-staged oral squamous cell carcinomas with a tumor infiltration depth below 4 mm. / Boeve, Koos; Mastik, Mirjam F; Slagter-Menkema, Lorian et al.
In: Head and Neck: Journal of the Sciences and Specialties of the Head and Neck, Vol. 43, No. 9, 09.2021, p. 2688-2697.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Cortactin expression assessment improves patient selection for a watchful waiting strategy in pT1cN0-staged oral squamous cell carcinomas with a tumor infiltration depth below 4 mm

AU - Boeve, Koos

AU - Mastik, Mirjam F

AU - Slagter-Menkema, Lorian

AU - van Dijk, Boukje A C

AU - Roodenburg, Jan L N

AU - van der Laan, Bernard F A M

AU - Witjes, Max J H

AU - van der Vegt, Bert

AU - Schuuring, Ed

PY - 2021/9

Y1 - 2021/9

N2 - Background In this feasibility study we aimed to evaluate the value of previously reported molecular tumor biomarkers associated with lymph node metastasis in oral squamous cell carcinoma (OSCC) to optimize neck strategy selection criteria.Methods The association between expression of cortactin, cyclin D1, FADD, RAB25, and S100A9 and sentinel lymph node status was evaluated in a series of 87 (cT1-2N0) patients with OSCC treated with primary resection and SLNB procedure.Results Tumor infiltration depth and tumor pattern of invasion were independent prognostic markers for SLN status, while none of the tumor makers showed a better prognostic value to replace SLNB as neck staging technique in the total cohort. However, in the subgroup of patients with pT1N0 OSCC, cortactin expression (OR 16.0, 95%CI 2.0-127.9) was associated with SLN classification.Conclusions Expression of cortactin is a promising immunohistochemical tumor marker to identify patients at low risk that may not benefit from SLNB or END.

AB - Background In this feasibility study we aimed to evaluate the value of previously reported molecular tumor biomarkers associated with lymph node metastasis in oral squamous cell carcinoma (OSCC) to optimize neck strategy selection criteria.Methods The association between expression of cortactin, cyclin D1, FADD, RAB25, and S100A9 and sentinel lymph node status was evaluated in a series of 87 (cT1-2N0) patients with OSCC treated with primary resection and SLNB procedure.Results Tumor infiltration depth and tumor pattern of invasion were independent prognostic markers for SLN status, while none of the tumor makers showed a better prognostic value to replace SLNB as neck staging technique in the total cohort. However, in the subgroup of patients with pT1N0 OSCC, cortactin expression (OR 16.0, 95%CI 2.0-127.9) was associated with SLN classification.Conclusions Expression of cortactin is a promising immunohistochemical tumor marker to identify patients at low risk that may not benefit from SLNB or END.

KW - lymph node classification

KW - molecular marker

KW - oral cancer

KW - oral squamous cell carcinoma

KW - sentinel lymph node biopsy

KW - SENTINEL NODE BIOPSY

KW - LYMPHATIC DRAINAGE PATTERNS

KW - ELECTIVE NECK DISSECTION

KW - 11Q13 AMPLIFICATION

KW - FADD EXPRESSION

KW - CYCLIN D1

KW - CANCER

KW - OVEREXPRESSION

KW - METASTASIS

KW - PREDICTOR

U2 - 10.1002/hed.26746

DO - 10.1002/hed.26746

M3 - Article

C2 - 34008248

SN - 1043-3074

VL - 43

SP - 2688

EP - 2697

JO - Head and Neck: Journal of the Sciences and Specialties of the Head and Neck

JF - Head and Neck: Journal of the Sciences and Specialties of the Head and Neck

IS - 9

ER -

Boeve K, Mastik MF, Slagter-Menkema L, van Dijk BAC , Roodenburg JLN, van der Laan BFAM et al. Cortactin expression assessment improves patient selection for a watchful waiting strategy in pT1cN0-staged oral squamous cell carcinomas with a tumor infiltration depth below 4 mm. Head and Neck: Journal of the Sciences and Specialties of the Head and Neck. 2021 Sept;43(9):2688-2697. Epub 2021 May 19. doi: 10.1002/hed.26746

Cortactin expression assessment improves patient selection for a watchful waiting strategy in pT1cN0-staged oral squamous cell carcinomas with a tumor infiltration depth below 4 mm

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this